Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

Oncology portfolio surges 35% as Ziihera launches and Xywav sustains momentum.

Jazz (JAZZ) Q3 2026 Earnings Call Transcript ↗

November 02, 2026

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology...

Topics Earnings

Jazz Pharmaceuticals Q3 Earnings Call Highlights ↗

November 02, 2026

Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 Results In Line as Raised Guidance Sparks After-Hours Surge ↗

Topics Cannabis Earnings

November 02, 2026

Via Chartmill

Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy Lifting ↗

October 22, 2026

Via Chartmill

Topics Cannabis

Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock ↗

October 09, 2026

Via Chartmill

Cannabis Stocks Aren’t a Recovery Trade: Narrow Leadership Splits Quality and Momentum ↗

October 06, 2026

Via Chartmill

Topics Cannabis

Jazz Pharmaceuticals (NASDAQ:JAZZ) surprises with Q3 2026 sales, full-year sales guidance is optimistic

November 02, 2026

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.4% year on year to $1.24 bill...

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect. Jazz Pharmaceuticals be...

What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings

October 31, 2026

Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine ↗

October 27, 2026

Jazz Pharmaceuticals' strategy is starting to pay dividends.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

3 Healthcare Stocks That Concern Us

October 16, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Cannabis Stocks: A Profitability Turnaround Is Brewing Beneath Weak Price Action ↗

September 22, 2026

Via Chartmill

Topics Cannabis

Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Stock Trading Below Its Worth ↗

September 02, 2026

Via Chartmill

Cannabis Rally Turns Selective as Investors Reward Pharma-Tinged Names ↗

August 29, 2026

Via Chartmill

Topics Cannabis

3 of Wall Street’s Favorite Stocks That Fall Short

October 14, 2026

Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks

September 29, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NAS...

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B ↗

Topics Artificial Intelligence Intellectual Property

September 20, 2026

Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the...

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the...

Topics Cannabis

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands ↗

September 20, 2026

Actio could make Jazz's growing epilepsy franchise even stronger.

Topics Cannabis

Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Opportunity ↗

August 12, 2026

Via Chartmill

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? ↗

September 18, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

3 Cash-Producing Stocks We’re Skeptical Of

September 11, 2026

Jazz Pharmaceuticals’s 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was ...

Topics Retirement

2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead

September 11, 2026

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...

Topics Stocks

1 Value Stock with Exciting Potential and 2 We Brush Off

September 08, 2026

Check out the companies making headlines yesterday: Jazz Pharmaceuticals (NASDAQ:JAZZ): Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) rose by 2.5% on ...

Topics Energy Retirement

Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere

September 01, 2026

What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 2.5% in the afternoon session after the company announced positive Phase...

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

August 31, 2026

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic...

Topics Artificial Intelligence

Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA ↗

August 25, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Topics Cannabis

3 Profitable Stocks with Questionable Fundamentals

August 14, 2026

Revenue hit $1.2 billion with oncology sales surging and Xywav demand accelerating.

Topics Economy

Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript ↗

August 10, 2026

Jazz Pharmaceuticals delivered a positive Q2, with a strong 16% year-over-year revenue increase driven primarily by its oncology and rare disease portfolios....

Topics Earnings

5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call

August 10, 2026

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% from a year earlier, as growth across its sleep, epilepsy and oncology portfolios drove record quarterly...

Topics Earnings

Jazz Pharmaceuticals Q2 Earnings Call Highlights ↗

August 03, 2026